TY - JOUR
T1 - Pair Box 8 (PAX8) protein expression in high grade, late stage (stages III and IV) ovarian serous carcinoma
AU - Mhawech-Fauceglia, Paulette
AU - Wang, Dan
AU - Samrao, Damanzoopinder
AU - Godoy, Heidi
AU - Ough, Faith
AU - Liu, Song
AU - Pejovic, Tanja
AU - Lele, Shashikant
PY - 2012/10
Y1 - 2012/10
N2 - Objectives: Pair-Box 8 (PAX8) is a transcription factor which has been found to be overexpressed in ovarian serous carcinoma (OSC). Silencing PAX8 by using shRNA led to a drop in cell viability in ovarian cancer cell lines, suggesting its use as a targeted therapeutic agent. The prognostic value of PAX8 in OSC is still widely unknown. The aim of this study was to evaluate PAX8 as a prognostic biomarker in patients with advanced stage OSC. Methods: PAX8 was evaluated using immunohistochemistry on a tissue microarray of 148 OSC and the expression was correlated to the following clinico-pathologic variables; age of diagnosis, tumor stage, optimal debulking, recurrence free survival (RFS) and overall survival (OS). Results: We found that PAX8 was expressed in 61% of cases. There was no association between PAX8 and tumor stage, optimal debulking and disease recurrence. In addition, PAX8 failed to have a predictive value in disease outcome. Conclusion: Despite showing that PAX8 protein is not a useful predictive marker in patients with high grade, advanced stage OSC, its overexpression in a large number of these cases makes the inhibition of PAX8 a very attractive targeted therapy.
AB - Objectives: Pair-Box 8 (PAX8) is a transcription factor which has been found to be overexpressed in ovarian serous carcinoma (OSC). Silencing PAX8 by using shRNA led to a drop in cell viability in ovarian cancer cell lines, suggesting its use as a targeted therapeutic agent. The prognostic value of PAX8 in OSC is still widely unknown. The aim of this study was to evaluate PAX8 as a prognostic biomarker in patients with advanced stage OSC. Methods: PAX8 was evaluated using immunohistochemistry on a tissue microarray of 148 OSC and the expression was correlated to the following clinico-pathologic variables; age of diagnosis, tumor stage, optimal debulking, recurrence free survival (RFS) and overall survival (OS). Results: We found that PAX8 was expressed in 61% of cases. There was no association between PAX8 and tumor stage, optimal debulking and disease recurrence. In addition, PAX8 failed to have a predictive value in disease outcome. Conclusion: Despite showing that PAX8 protein is not a useful predictive marker in patients with high grade, advanced stage OSC, its overexpression in a large number of these cases makes the inhibition of PAX8 a very attractive targeted therapy.
KW - Disease outcome
KW - Immunoexpression
KW - Ovarian serous cancer
KW - PAX8
UR - http://www.scopus.com/inward/record.url?scp=84865699113&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84865699113&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2012.06.012
DO - 10.1016/j.ygyno.2012.06.012
M3 - Article
C2 - 22705448
AN - SCOPUS:84865699113
SN - 0090-8258
VL - 127
SP - 198
EP - 201
JO - Gynecologic oncology
JF - Gynecologic oncology
IS - 1
ER -